GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced Sarcoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Doxorubicin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
Indications Leiomyosarcoma; Liposarcoma; Osteosarcoma; Sarcoma; Synovial sarcoma
Focus Therapeutic Use
Acronyms GALLANT

04 Jun 2024 Interim Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Results (n=17) assessing the efficacy and safety using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second or third-line therapy for advanced leiomyosarcoma, presented at the 48th European Society for Medical Oncology Congress.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com